Walleye Capital’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
Other funds holding ATRA
RG
VCM
EC
Walleye Capital's ATRA Position: Q1 2026 in Review
Walleye Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 12,169 shares — an estimated $220K sold.
Walleye Capital first reported a position in ATRA in Q4 2019 and held it in 6 quarters. The position peaked at $1.42M in Q3 2022. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.
- Walleye Capital reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
- Walleye Capital sold 12,169 Atara Biotherapeutics shares in Q1 2026, an estimated $220K.
- Walleye Capital first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 6 quarters.
- Walleye Capital's Atara Biotherapeutics position peaked at $1.42M in Q3 2022.
- 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.
Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.